TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05556941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Group Intervention
Description: The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy standard care
Description: Occupational therapy standard care
Study: NCT04059939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading
Description: Small group reading instruction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading
Description: Small group reading instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Management
Description: small group anxiety management skills instruction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Business as Usual
Description: Classroom Business as Usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Control (math practice)
Description: Attention Control (math practice)
Study: NCT02425423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New thickened formula
Study: NCT02842008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
Study: NCT04472494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT01912053

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Therasphere® in association with Gemcitabine and Cisplatin
Description: Therasphere® is a radioelement
Study: NCT03862872

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-Aging Formula
Description: Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Fish Oil
Description: The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Placebo
Description: The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
Study: NCT00884845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM02734 and erlotinib
Description: PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
Study: NCT00899977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Study: NCT02524626

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation
Description: Vagus stimulation
Study: NCT00953732

Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study: NCT03452865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (same ml of the study drug)
Study: NCT01853189

Intervention type: OTHER
Group type: OTHER
Intervention: OMT + Usual Care
Description: patients from this group received 6 sessions of OMT

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
Study: NCT03374293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Antibody
Description: Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
Study: NCT01544634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qvar 50
Description: Qvar 50, 1 puff bd for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qvar 100
Description: Qvar 100, 2 puffs bd for 6 weeks
Study: NCT04198571

Intervention type: DRUG
Intervention: Zinforo (ceftaroline fosamil)
Description: IV Solution
Study: NCT01913262

Intervention type: BEHAVIORAL
Intervention: Standard Behavioral treatment
Description: Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
Study: NCT02876952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH VOLUME (HV) Supervised exercise
Description: Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet Recommendations
Description: Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction.
Study: NCT00564278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antidepressant therapy (SADT)
Description: Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antidepressant therapy (SADT)
Description: Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational antidepressant therapy (MADT)
Description: The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
Study: NCT03365960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Rind
Description: watermelon rind

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Flesh
Description: watermelon flesh

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Seeds
Description: watermelon seeds

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Comparator
Study: NCT02399969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
Study: NCT02298036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Remote) Cognitive Behaviour Therapy
Description: Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
Study: NCT01526278

Intervention type: DRUG
Group type: OTHER
Intervention: Maxmarvil®
Description: Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
Study: NCT02567097

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Incentive
Description: Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Incentive
Description: Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Incentive
Description: Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Incentive
Description: Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
Study: NCT02758197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
Study: NCT04386161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled exercise program
Description: 45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
Study: NCT00790556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8245
Description: MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
Study: NCT03061487

Intervention type: PROCEDURE
Intervention: Open Surgical Treatment of Aneurysm (Aneurysmectomy)
Description: Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).

Intervention type: PROCEDURE
Intervention: Open Surgical Treatment of Aneurysm (Aneurysmectomy)
Description: Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
Study: NCT01679028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 Group A
Description: 150mg single dose on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group A
Description: 150mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group B
Description: 300mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 Group B
Description: 300mg single dose
Study: NCT02876952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Recommendations
Description: Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Recommendations
Description: Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction.
Study: NCT01679028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group C
Description: 225mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 Group C
Description: 225mg bid
Study: NCT03000322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
Study: NCT04678609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
Study: NCT02186899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Femoral Sciatic Obturator nerve blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia femoral bolus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia femoral continuous
Study: NCT05867680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mothers and Babies Course (eMB)
Description: The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
Study: NCT00707980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets
Study: NCT00348335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine 0.05%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocular lubricant
Study: NCT02020889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as 0.9% sodium chloride
Study: NCT03001908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glenohumeral mobilization-oscillation
Description: posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glenohumeral mobilization-oscillation
Description: posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glenohumeral mobilization-sustained
Description: posterior glide mobilization, sustained 4 x 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glenohumeral mobilization-sustained
Description: posterior glide mobilization, sustained 4 x 30 seconds
Study: NCT04752306

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
Study: NCT01560715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of autologous bone marrow stem cells
Description: One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.